{"schemaVersion":"wpf-profile-export-v1","exportedAt":"2026-09-24T04:09:40.568Z","profile":{"slug":"exenatide","name":"Exenatide","aliases":[],"category":"GLP-1 receptor agonist"},"synthesis":{"mechanism":"Exenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist. WPF organizes its research by formulation, type 2 diabetes outcomes, comparative studies, safety and tolerability, and other investigated questions. Formulation and dosing schedules differ across studies, so results from one preparation or population should not automatically be generalized to another.","evidence":"WPF already displays a deduplicated Exenatide research atlas with ranked source records and a separate set of directly attributable studies. The featured set includes a cardiovascular outcomes trial in type 2 diabetes (PMID 28910237), a randomized comparison with semaglutide extended-release exenatide (PMID 29246950), and a trial in alcohol use disorder (PMID 36066977). These address different questions; the latter must not be described as establishing treatment benefit from the brief source excerpt alone. Proposed ranks and tiers are discovery aids, not approved conclusions.","safety":"The current Directory entry has not promoted its screening inventory into a fully source-linked editorial synthesis. A paper may concern a different population, formulation, comparator, or endpoint, and a review does not replace examination of the underlying studies. The absence of published citations in this Directory lane reflects its workflow state, not absence of research.","observationalBoundary":"De-identified self-reported experiences belong to WPF’s separate observational archive. They can preserve what contributors noticed and raise research questions, but cannot determine causation, treatment benefit, comparative safety, or event frequency. This profile does not treat an anecdote as controlled evidence.","openQuestions":"Which findings apply to each exenatide formulation and patient population? How do direct randomized comparisons differ from indirect or GLP-1 class-level claims? Which long-term and safety outcomes have adequate controlled evidence, and which reported effects remain uncertain? Answers require source-level appraisal with explicit limitations."},"completion":{"version":"wpf-profile-v1.1","verifiedSourceCount":0,"evidenceDepth":"limited_evidence","complete":false,"checks":[{"key":"overview","passed":true,"actual":367,"required":100,"severity":"blocking"},{"key":"evidence_summary","passed":true,"actual":582,"required":100,"severity":"blocking"},{"key":"safety_summary","passed":true,"actual":379,"required":100,"severity":"blocking"},{"key":"archive_boundary","passed":true,"actual":316,"required":75,"severity":"blocking"},{"key":"open_questions","passed":true,"actual":343,"required":75,"severity":"blocking"},{"key":"verified_sources","passed":false,"actual":0,"required":1,"severity":"blocking"},{"key":"evidence_depth_target","passed":false,"actual":0,"required":25,"severity":"warning"},{"key":"reviewed_sources","passed":false,"actual":0,"required":1,"severity":"blocking"},{"key":"chemistry","passed":false,"actual":false,"required":true,"severity":"blocking"},{"key":"regulatory_context","passed":false,"actual":0,"required":2,"severity":"blocking"},{"key":"claims","passed":false,"actual":0,"required":1,"severity":"blocking"},{"key":"claim_traceability","passed":true,"actual":0,"required":0,"severity":"blocking"},{"key":"regulatory_freshness","passed":true,"actual":0,"required":0,"severity":"warning"}],"failures":["verified_sources","evidence_depth_target","reviewed_sources","chemistry","regulatory_context","claims"]},"chemistry":null,"evidence":[],"regulatory":[],"claims":[],"correctionHistory":[],"boundaries":{"observationsAreEvidence":false,"completionIsPublicationApproval":false,"medicalAdvice":false}}